Biotech | November 12, 2021
Ronapreve gets the green light from CHMP to treat non-hospitalised Covid-19 patients
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
The centre has an initial capacity of 500 FTEs
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
Thermo Fisher Scientific expands diagnostics portfolio to support full qPCR assay development and testing workflow
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
The workshop had been organized by the department of surgery at Jawaharlal Nehru Medical College (JNMC), Aligarh Muslim University (AMU), along with the Association of Surgeons of Aligarh (ASA)
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
Subscribe To Our Newsletter & Stay Updated
